Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City. Certara’s management team will provide updates on the Company’s strategy, differentiated software and technology-driven services, and financial guidance for 2022. There will also be a demonstration of the Simcyp™ Simulator.
The live video webcast of the event, along with a slide presentation, will be available on Certara's Investor Relations website at https://ir.certara.com/events/event-details/certara-investor-day. A replay of the event will be archived on the Investor Relations website for 2 weeks following the event.
About Certara
Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
Certara Contact
Jieun W. Choe
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contacts:
Daniel Yunger
Kekst CNC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$9.96 |
Daily Change: | -0.57 -5.41 |
Daily Volume: | 1,213,977 |
Market Cap: | US$1.600B |
November 06, 2024 September 18, 2024 August 15, 2024 August 06, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB